JP2021524835A5 - - Google Patents

Info

Publication number
JP2021524835A5
JP2021524835A5 JP2020523746A JP2020523746A JP2021524835A5 JP 2021524835 A5 JP2021524835 A5 JP 2021524835A5 JP 2020523746 A JP2020523746 A JP 2020523746A JP 2020523746 A JP2020523746 A JP 2020523746A JP 2021524835 A5 JP2021524835 A5 JP 2021524835A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
cancer
tartrate
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020523746A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021524835A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/026094 external-priority patent/WO2019195753A1/en
Publication of JP2021524835A publication Critical patent/JP2021524835A/ja
Publication of JP2021524835A5 publication Critical patent/JP2021524835A5/ja
Pending legal-status Critical Current

Links

JP2020523746A 2018-04-05 2019-04-05 Axlキナーゼ阻害剤およびその使用 Pending JP2021524835A (ja)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US201862653394P 2018-04-05 2018-04-05
US62/653,394 2018-04-05
US201862663146P 2018-04-26 2018-04-26
US62/663,146 2018-04-26
US201862678980P 2018-05-31 2018-05-31
US62/678,980 2018-05-31
US201862688161P 2018-06-21 2018-06-21
US62/688,161 2018-06-21
US201862695609P 2018-07-09 2018-07-09
US62/695,609 2018-07-09
US201862698638P 2018-07-16 2018-07-16
US62/698,638 2018-07-16
US201862760882P 2018-11-13 2018-11-13
US62/760,882 2018-11-13
US201862767475P 2018-11-14 2018-11-14
US62/767,475 2018-11-14
US201862778856P 2018-12-12 2018-12-12
US62/778,856 2018-12-12
US201962813705P 2019-03-04 2019-03-04
US62/813,705 2019-03-04
PCT/US2019/026094 WO2019195753A1 (en) 2018-04-05 2019-04-05 Axl kinase inhibitors and use of the same

Publications (2)

Publication Number Publication Date
JP2021524835A JP2021524835A (ja) 2021-09-16
JP2021524835A5 true JP2021524835A5 (OSRAM) 2022-04-13

Family

ID=68101236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020523746A Pending JP2021524835A (ja) 2018-04-05 2019-04-05 Axlキナーゼ阻害剤およびその使用

Country Status (13)

Country Link
US (3) US11013741B1 (OSRAM)
EP (1) EP3773591A4 (OSRAM)
JP (1) JP2021524835A (OSRAM)
KR (1) KR20210003780A (OSRAM)
CN (1) CN112533602A (OSRAM)
AU (1) AU2019247498A1 (OSRAM)
BR (1) BR112020020246A8 (OSRAM)
CA (1) CA3096984A1 (OSRAM)
IL (1) IL277600A (OSRAM)
MX (1) MX2020010437A (OSRAM)
PH (1) PH12020551853A1 (OSRAM)
SG (1) SG11202009443RA (OSRAM)
WO (1) WO2019195753A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6433974B2 (ja) 2013-03-14 2018-12-05 トレロ ファーマシューティカルズ, インコーポレイテッド Jak2およびalk2阻害剤およびその使用方法
BR112020020246A8 (pt) 2018-04-05 2022-10-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de cinase axl e uso dos mesmos
WO2020023910A1 (en) 2018-07-26 2020-01-30 Tolero Pharmaceuticals, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
WO2021067772A1 (en) * 2019-10-04 2021-04-08 Sumitomo Dainippon Pharma Oncology, Inc. Axl inhibitor formulations
WO2022005881A1 (en) * 2020-06-29 2022-01-06 Bacainn Biotherapeutics, Inc. Probenecid compounds for the treatment of inflammasome-mediated lung disease
US20230277631A1 (en) * 2020-07-19 2023-09-07 Aravive Inc Diagnostic methods for cancer using axl decoy receptors
EP4464699A1 (en) * 2022-01-14 2024-11-20 Lisen Therapeutics, Inc. Pyrimidine-2,4-diamine derivatives as well as preparation method therefor and use thereof
WO2024097229A1 (en) * 2022-11-04 2024-05-10 Bacainn Biotherapeutics, Inc. Probenecid compounds for the treatment of inflammasome-mediated dermatological conditions

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
JP3053222B2 (ja) 1995-04-20 2000-06-19 ファイザー・インコーポレーテッド Mmpおよびtnf抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
CA2260898C (en) 1996-07-18 2002-05-14 Pfizer Limited Phosphinate based inhibitors of matrix metalloproteases
PL331895A1 (en) 1996-08-23 1999-08-16 Pfizer Arylosulphonylamino derivatives of hydroxamic acid
CA2239227C (en) 1996-10-01 2007-10-30 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compounds
DE69730151T2 (de) 1997-01-06 2005-08-04 Pfizer Inc. Cyclische sulfonderivate
AU721748B2 (en) 1997-02-03 2000-07-13 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
CA2279863A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
WO1998034918A1 (en) 1997-02-11 1998-08-13 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
ID23668A (id) 1997-08-08 2000-05-11 Pfizer Prod Inc Turunan asam ariloksiarilsulfonilamino hidroksamat
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
JP4462654B2 (ja) 1998-03-26 2010-05-12 ソニー株式会社 映像素材選択装置及び映像素材選択方法
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
DK1004578T3 (da) 1998-11-05 2004-06-28 Pfizer Prod Inc 5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater
IL143236A0 (en) 1998-12-16 2002-04-21 Warner Lambert Co Treatment of arthritis with mek inhibitors
US6511993B1 (en) 1999-06-03 2003-01-28 Kevin Neil Dack Metalloprotease inhibitors
IN191496B (OSRAM) * 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
HUP0301117A3 (en) 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
BR0111280A (pt) 2000-06-05 2003-06-10 Dong A Pharm Co Ltd Novos derivados de oxazolidinona e um processo para a preparação dos mesmos
WO2002006213A2 (en) 2000-07-19 2002-01-24 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
EP1964839A3 (en) 2000-08-18 2008-11-05 Millennium Pharmaceuticals, Inc. Quinazoline derivatives as kinase inhibitors
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
RU2343148C2 (ru) 2002-02-01 2009-01-10 Райджел Фармасьютикалз, Инк Соединения 2,4-пиримидиндиаминов и их применение
US7799827B2 (en) 2002-03-08 2010-09-21 Eisai Co., Ltd. Macrocyclic compounds useful as pharmaceuticals
TWI343377B (en) 2002-03-13 2011-06-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003231231A1 (en) 2002-05-06 2003-11-11 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
JP4608852B2 (ja) 2002-10-15 2011-01-12 チッソ株式会社 液晶性ビニルケトン誘導体およびその重合体
JP2006151810A (ja) 2002-12-26 2006-06-15 Daiichi Asubio Pharma Co Ltd ジヒドロチエノキノリン誘導体及びそれを含む細胞接着阻害剤
DE602004021472D1 (en) 2003-02-20 2009-07-23 Smithkline Beecham Corp Pyrimiidinverbindungen
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
TWI378923B (en) 2003-08-15 2012-12-11 Novartis Ag Pyrimidine derivatives
BRPI0414544A (pt) 2003-09-18 2006-11-07 Novartis Ag 2,4-di-(fenilamino) pirimidinas úteis no tratamento de transtornos proliferativos
ES2344007T3 (es) 2003-10-14 2010-08-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibidores proteina quinasa.
WO2005082892A2 (en) 2004-02-17 2005-09-09 Dr. Reddy's Laboratories Ltd. Triazole compounds as antibacterial agents and pharmaceutical compositions containing them
EP1737843B1 (en) 2004-04-09 2011-02-23 Merck Sharp & Dohme Corp. Inhibitors of akt activity
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
CA2604284A1 (en) 2005-04-28 2006-11-02 Supergen, Inc. Protein kinase inhibitors
US20060270694A1 (en) 2005-05-03 2006-11-30 Rigel Pharmaceuticals, Inc. JAK kinase inhibitors and their uses
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
WO2007014011A2 (en) 2005-07-21 2007-02-01 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
EP1923388A4 (en) 2005-08-12 2011-03-09 Takeda Pharmaceutical BRAIN / NEURONAL CELL PROTECTIVE AGENT AND THERAPEUTIC AGENT FOR SLEEP DISORDERS
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US7528143B2 (en) 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
BRPI0621027A2 (pt) 2006-01-13 2011-11-29 Pharmacyclics Inc composto, composição farmacêutica
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR20080110998A (ko) 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Jak­2 조절자로서 4­아릴­2­아미노­피리미딘 또는 4­아릴­2­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
JP2009528295A (ja) 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ, インコーポレイテッド Jak経路の阻害のための組成物および方法
EP2054392A2 (en) 2006-06-15 2009-05-06 Boehringer Ingelheim International GmbH 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase c-alpha
PL2526933T3 (pl) 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
WO2008055233A1 (en) 2006-10-31 2008-05-08 Supergen, Inc. Protein kinase inhibitors
ES2403546T3 (es) 2006-11-03 2013-05-20 Pharmacyclics, Inc. Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
BRPI0722383A2 (pt) 2006-12-08 2012-06-05 Irm Llc compostos inibidores de proteìna quinase, composições contendo os mesmos bem como seus usos
TW200902010A (en) 2007-01-26 2009-01-16 Smithkline Beecham Corp Anthranilamide inhibitors of aurora kinase
ES2702362T3 (es) 2007-01-31 2019-02-28 Ym Biosciences Australia Pty Compuestos a base de tiopirimidina y usos de los mismos
CN101657431A (zh) 2007-03-01 2010-02-24 休普基因公司 嘧啶-2,4-二胺衍生物及其作为jak2激酶抑制剂的用途
AU2008221278A1 (en) 2007-03-01 2008-09-04 Supergen, Inc. Pyrimidine-2,4-diamine derivatives and their use as JAK2 kinase inhibitors
US7834024B2 (en) 2007-03-26 2010-11-16 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US20120101113A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
SG10201508035TA (en) 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
CA2682733A1 (en) 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors
WO2008137605A1 (en) 2007-05-04 2008-11-13 Irm Llc Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors
WO2009010794A1 (en) 2007-07-19 2009-01-22 Astrazeneca Ab 2,4-diamino-pyrimidine derivatives
AU2008298948B2 (en) 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
EP2214675B1 (en) 2007-10-25 2013-11-20 Genentech, Inc. Process for making thienopyrimidine compounds
WO2009080638A2 (en) 2007-12-20 2009-07-02 Cellzome Limited Sulfamides as zap-70 inhibitors
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CA2730930C (en) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
WO2010011349A2 (en) 2008-07-25 2010-01-28 Supergen, Inc. Pyrimidine-2,4-diamine jak2 kinase inhibiting anti-inflammation use
RU2011108563A (ru) 2008-08-05 2012-09-10 Таргеджен, Инк. (US) Способы лечения талассемии
PL2389372T3 (pl) 2009-01-23 2016-02-29 Rigel Pharmaceuticals Inc Kompozycje i sposoby hamowania szlaku JAK
JP2012517426A (ja) 2009-02-09 2012-08-02 アステックス ファーマシューティカルズ インコーポレイテッド ピロロピリミジニルaxlキナーゼ阻害剤
US20120040955A1 (en) 2009-04-14 2012-02-16 Richard John Harrison Fluoro substituted pyrimidine compounds as jak3 inhibitors
RU2595718C2 (ru) 2009-09-09 2016-08-27 Селджен Авиломикс Рисерч,Инк. Ингибиторы pi3-киназы и их применение
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
CN102791697A (zh) 2009-10-12 2012-11-21 瑞科西有限公司 作为TBKL和/或IKKε抑制剂的氨基-嘧啶化合物
CN102791690B (zh) 2010-01-29 2015-12-02 大塚制药株式会社 作为抗癌药的二取代吡啶衍生物
NZ772688A (en) 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
CA2794731C (en) 2010-06-18 2019-03-19 Genentech, Inc. Anti-axl antibodies and methods of use
US9249124B2 (en) 2011-03-30 2016-02-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase inhibitors and methods of making and using thereof
EP3628665B1 (en) * 2011-04-01 2022-11-02 University of Utah Research Foundation Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase
US8703767B2 (en) 2011-04-01 2014-04-22 University Of Utah Research Foundation Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors
EA201490265A1 (ru) 2011-07-13 2014-12-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
CN110801454A (zh) 2011-10-19 2020-02-18 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的用途
CN103087077B (zh) 2011-11-03 2016-05-18 上海希迈医药科技有限公司 噻吩并嘧啶和呋喃并嘧啶类衍生物、其制备方法及其在医药上的应用
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
WO2013173518A1 (en) 2012-05-16 2013-11-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2013184572A1 (en) 2012-06-04 2013-12-12 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
US8703981B2 (en) 2012-08-03 2014-04-22 Xerox Corporation Lignosulfonate compounds for solid ink applications
ES2733576T3 (es) 2012-08-06 2019-12-02 Acea Therapeutics Inc Nuevos compuestos de pirrolopirimidina como inhibidores de proteína cinasas
KR101446742B1 (ko) 2012-08-10 2014-10-01 한국화학연구원 N2,n4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CA2883641C (en) * 2012-09-18 2021-09-14 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CN104812756A (zh) 2012-09-26 2015-07-29 曼凯德公司 多激酶通路抑制剂
SG11201503842PA (en) 2012-11-15 2015-06-29 Pharmacyclics Inc Pyrrolopyrimidine compounds as kinase inhibitors
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US10322125B2 (en) 2013-02-22 2019-06-18 Emory University TGF-beta enhancing compositions for cartilage repair and methods related thereto
US9708326B2 (en) 2013-02-25 2017-07-18 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
EP2968341A4 (en) 2013-03-14 2016-11-23 Pharmacyclics Llc COMBINATIONS OF BURTON TYROSINE KINASE INHIBITORS AND CYP3A4 INHIBITORS
JP6433974B2 (ja) 2013-03-14 2018-12-05 トレロ ファーマシューティカルズ, インコーポレイテッド Jak2およびalk2阻害剤およびその使用方法
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
TW201524952A (zh) 2013-03-15 2015-07-01 Araxes Pharma Llc Kras g12c之共價抑制劑
AU2014251028A1 (en) 2013-04-08 2015-11-05 Janssen Pharmaceutica Nv Ibrutinib combination therapy
US9637487B2 (en) 2013-07-02 2017-05-02 Pharmacyclics Llc Purinone compounds as kinase inhibitors
CA2925124A1 (en) 2013-09-30 2015-04-02 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
JP6559123B2 (ja) 2013-10-10 2019-08-14 アラクセス ファーマ エルエルシー Krasg12cの阻害剤
IL292510A (en) 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
WO2016105529A1 (en) 2014-12-23 2016-06-30 Cephalon, Inc. Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives
PL3298021T3 (pl) 2015-05-18 2019-11-29 Tolero Pharmaceuticals Inc Proleki alvocidibu o zwiększonej biodostępności
WO2017091546A1 (en) 2015-11-23 2017-06-01 Trustees Of Boston University Methods and compositions relating to chimeric antigen receptors
BR112020020246A8 (pt) 2018-04-05 2022-10-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de cinase axl e uso dos mesmos

Similar Documents

Publication Publication Date Title
JP2022058395A5 (OSRAM)
US11291667B2 (en) Combination therapy involving diaryl macrocyclic compounds
JP2024514339A5 (OSRAM)
JP5855250B2 (ja) イミダゾオキサジン化合物による抗腫瘍効果増強剤
CN115624550B (zh) 一种用于治疗胃癌的喹啉衍生物
JPWO2013100014A1 (ja) 抗腫瘍剤の効果増強剤
JP6855488B2 (ja) 食道癌を治療するためのキノリン誘導体の使用とその治療方法、医薬組成物及びキット
JP2007521340A5 (OSRAM)
JP2022511029A5 (OSRAM)
WO2017152706A1 (zh) 吡啶胺基嘧啶衍生物的盐及其制备方法和应用
CN111643503A (zh) 用于治疗非小细胞肺癌的喹啉衍生物
JP2021501766A5 (OSRAM)
JP4852605B2 (ja) 放射線治療増強剤
JP2022535850A5 (OSRAM)
CN103534250B (zh) 用于治疗免疫障碍的被取代的吲哚衍生物
KR20110014192A (ko) 4-(3-클로로-2-플루오로아닐리노)-7-메톡시-6-([1-(n-메틸카르바모일메틸)피페리딘-4-일]옥시)퀴나졸린의 푸마레이트 염
EP4316491A1 (en) Application of compound in preparation of inhibitory drug targeting erbb2 mutant
EP1966192B1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
WO2022171138A1 (zh) 一种含氮杂环化合物的晶型、其制备方法及应用
KR102501514B1 (ko) 2'-아미노-6-(2-아미노-6-(1-이소프로필피페리딘-4-일)-5-메틸피리미딘-4-일)-3'-플루오로-[2,4'-바이피리딘]-5-올 3염산염 및 이를 포함하는 약제학적 조성물
HK40105285A (en) Application of compound in preparation of inhibitory drug targeting erbb2 mutant
CA3010654C (en) Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof
EA047153B1 (ru) Способы лечения гематологических злокачественных новообразований с применением 2-(2,6-диоксопиперидин-3-ил)-4-((2-фтор-4-((3-морфолиноазетидин-1-ил)метил)бензил)амино)изоиндолин-1,3-диона
JP5581200B2 (ja) シチジン誘導体及びカルボプラチンを含有する抗腫瘍剤
CN118891255A (zh) 新化合物及其抑制检查点激酶2的用途